Module

New Therapies for Chronic Hepatitis C

Source: Hepatitis Annual Update 2006

New Therapies for Chronic Hepatitis C

Program Director: Emmet B. Keeffe, MD, MACP

Faculty:

Gary L. Davis, MD

CME CREDIT INFORMATION

Release Date: 08/25/06

Expiration Date: 08/24/07

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.0 contact hour (0.1 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss prospective therapeutic targets inherent in the mechanism of hepatitis C virus (HCV) viral replication
Explain the rationale for and potential utility of novel agents under development for the treatment of HCV
Summarize recent data from clinical trials of investigational new anti-HCV drugs

Topics covered include:

Introduction
The HCV Genome and Replicative Cycle
Replication of HCV and Targets for Virus Inhibition
RNA Transport to the Endoplasmic Reticulum
HCV Translation
Viral RNA Transcription
Virus Assembly
Future Directions
Summary—Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.